Curis is a clinical-stage biotech focused on developing a single drug candidate, emavusertib (CA-4948), for blood cancers. Emavusertib is an oral small molecule that simultaneously inhibits two proteins—IRAK4 and FLT3—that drive certain leukemias and lymphomas. The core thesis is that many B-cell blood cancers are fueled by two parallel signaling pathways (BCR and TLR), and that current standard-of-care BTK inhibitors only block one of them. By blocking the TLR pathway via IRAK4 inhibition, emavusertib combined with a BTK inhibitor creates a dual blockade that Curis believes can produce deeper responses, including complete remissions. Curis has no approved products and no revenue. Its lead program is TakeAim Lymphoma, a registrational Phase 1/2 study of emavusertib plus ibrutinib in relapsed/refractory primary CNS lymphoma, an ultra-rare indication with no FDA-approved therapies. Both the FDA and EMA have provided supportive guidance for an accelerated approval pathway. Curis is targeting full enrollment in roughly 12–18 months from early 2025, with a potential regulatory submission in 2027. A second active program, TakeAim CLL, evaluates emavusertib plus zanubrutinib in frontline CLL patients who have achieved only a partial response on a BTK inhibitor alone. An AML program is deprioritized pending additional capital. Curis funds operations through equity financings and licenses emavusertib from Aurigene Discovery Technologies, with royalty and milestone obligations attached. The likely long-term commercialization path involves partnering with a larger pharmaceutical company.